Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin PK Study in Pediatric Duchenne Muscular Dystrophy (CHERISH)
NCT07172971Phase 1Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of empagliflozin in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Medication dose at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07172971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172971.